
Sign up to save your podcasts
Or


The utility of prostate-specific antigen (PSA) screening for prostate cancer detection is impacted by detection of cancers with low risk of mortality. Editorialist Jeffrey J. Tosoian, MD, MPH, discusses a pragmatic approach to prostate cancer screening with JAMA Deputy Editor Mary L. (Nora) Disis, MD. Related Content:
By JAMA Network4.6
162162 ratings
The utility of prostate-specific antigen (PSA) screening for prostate cancer detection is impacted by detection of cancers with low risk of mortality. Editorialist Jeffrey J. Tosoian, MD, MPH, discusses a pragmatic approach to prostate cancer screening with JAMA Deputy Editor Mary L. (Nora) Disis, MD. Related Content:

38,594 Listeners

43,737 Listeners

27,167 Listeners

135 Listeners

321 Listeners

545 Listeners

695 Listeners

498 Listeners

6,441 Listeners

302 Listeners

263 Listeners

3,360 Listeners

21 Listeners

13 Listeners

10 Listeners

8 Listeners

20 Listeners

30 Listeners

91 Listeners

515 Listeners

368 Listeners

18 Listeners

369 Listeners